FDA Accepts Tildrakizumab-asmn sBLA for Active Psoriatic Arthritis

The FDA has accepted for review a supplemental Biologics License Application (sBLA) for Sun Pharma’s tildrakizumab-asmn to treat adults with active psoriatic arthritis.¹ This represents a significant step in the lifecycle management of a humanized monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23). By inhibiting the interaction with the IL-23 receptor, the treatment aims to prevent the release of pro-inflammatory cytokines and chemokines. The FDA action date for this regulatory decision is anticipated by October 29, 2026.

How Does this Impact the Development of Interleukin-23 Inhibitors?

Expanding the indications of an existing biologic is a critical strategy for addressing unmet needs in psoriatic disease, where approximately one in three patients with psoriasis eventually develops psoriatic arthritis.¹ Since its initial 2018 approval for moderate-to-severe plaque psoriasis, tildrakizumab-asmn has seen its label expand to include scalp and nail psoriasis in 2024 and 2025, respectively. Rick Ascroft, CEO, Sun Pharma North America, noted, in a press release,¹ “For many people living with psoriatic disease, joint symptoms often add another layer of burden.” These expansions highlight the importance of long-term clinical follow-up, which for this biologic currently includes 5 years of data showing a well-characterized safety profile.

What Clinical Evidence Underpins the Proposed Expansion for Psoriatic Arthritis?

The current sBLA submission is supported by data from the INSPIRE-1 and INSPIRE-2 Phase III clinical studies.¹ These 52-week global, multicenter, randomized, double-blind, placebo-controlled trials evaluated the efficacy and safety of a 100 mg dose in adult patients with active psoriatic arthritis. Regarding the strategic direction of the product, Ascroft stated, in the press release,¹ “As we continue to strengthen Sun Pharma’s innovative portfolio, we look forward to working with the FDA throughout the review process. As the only HCP-administered IL-23 biologic, our ambition is that ILUMYA becomes a differentiated first-choice advanced systemic treatment for active psoriatic arthritis.” The move toward a HCP administered option for psoriatic arthritis differentiates the product in a competitive market while leveraging a global infrastructure that has already secured marketing authorization from over 55 health authorities. From a safety perspective, common adverse reactions recorded in trials include upper respiratory infections, injection site reactions, and diarrhea. The review process will continue through 2026, building upon the treatment's existing history of supporting nearly 140,000 patients worldwide.

What Else Is Sun Pharma Developing?

The manufacturer's specialty portfolio, which accounts for approximately 20% of global sales, is expanding beyond immunology into onco-dermatology.² A significant milestone in this expansion is the US availability of cosibelimab-ipdl for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (aCSCC) who are not candidates for curative surgery or radiation. This agent represents a technical evolution in checkpoint inhibition as a programmed death-ligand 1 (PD-L1) antibody that preserves programmed death-ligand 2 (PD-L2) signaling. Ascroft stated, in a press release,² “UNLOXCYT is an evolution in checkpoint inhibition, combining durable efficacy with a proven tolerability profile for a group of aCSCC patients who traditionally would struggle to strike that therapeutic balance.”

How Is the Oncology-dermatology Portfolio Evolving with New Checkpoint Inhibitors?

The clinical utility of this PD-L1 therapy is evidenced by a 71% disease control rate in the CK-301-101 trial.² Ann W. Silk, MD, MS, medical oncologist, Dana-Farber Cancer Institute, explains, in the press release,² “Because these patients tend to be older and have multiple comorbidities, it’s extremely valuable to have a therapy that offers durable disease control and proven tolerability.” This matters to development teams because the multifaceted mechanism of action involves both adaptive and innate immune responses while maintaining PD-L2 signaling.

What Clinical Outcomes Define the Performance of this Novel Antibody?

The product requires a limited distribution network for its 1,200 mg intravenous infusion administered every three weeks.² While common reactions include fatigue and musculoskeletal pain, long-term data confirms durable efficacy and a proven tolerability profile. These advancements reinforce the manufacturer's established reach across six continents.

References

1. Sun Pharmaceutical Industries Limited. Sun Pharma announces US FDA acceptance of supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis. News release. March 16, 2026.
2. Sun Pharmaceutical Industries Limited. Sun Pharma announces the availability of UNLOXCYT (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma (aCSCC). News release. January 15, 2026. Accessed March 16, 2026. https://sunpharma.com/usa/wp-content/uploads/sites/2/2026/01/UNLOXCYT-Commercial-Launch-Press-Release.pdf